Insulet (NASDAQ:PODD) Upgraded at Barclays

Barclays upgraded shares of Insulet (NASDAQ:PODD) to a hold rating in a report issued on Wednesday,Zacks reports.

A number of other equities analysts have also recently weighed in on the company. TD Cowen reduced their price target on Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a report on Thursday, August 6th. Leerink Partners lowered Insulet from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $247.00 to $145.00 in a report on Thursday, August 6th. Wall Street Zen cut Insulet from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 9th. Truist Financial reaffirmed a “hold” rating and set a $153.00 target price (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 target price on the stock. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $193.48.

Insulet Stock Up 0.6%

PODD opened at $135.28 on Wednesday. The company has a fifty day moving average of $141.73 and a two-hundred day moving average of $159.64. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 1.06 and a beta of 1.11. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the prior year, the company posted $1.17 EPS. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts expect that Insulet will post 6.51 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Insulet during the second quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership grew its holdings in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Man Group plc purchased a new stake in Insulet in the 2nd quarter valued at $78,746,000. Amundi increased its stake in shares of Insulet by 13.6% in the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after acquiring an additional 60,929 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Insulet in the 2nd quarter worth $64,921,000.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.